button bars forest bayes pooled summary circles
 
Statistically conclusive or suggested result Inconclusive results Uncertain results Safety results

es-BC - HER2 negative - (neo)adjuvant (NA) breast cancer - HER2-positive es-BC - HER2 negative - (neo)adjuvant (NA)

es-BC - HER2 positive - (neo)adjuvant (NA) breast cancer - HER2-positive es-BC - HER2 positive - (neo)adjuvant (NA)

versus lapatinib plus epirubicin and cyclophosphamide followed by docetaxel
trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel vs. lapatinib plus epirubicin and cyclophosphamide followed by docetaxel 1 none-

statistically conclusive 48 % increase in pCR but the degree if certainty is unassessable

-

la/mBC - HER2 positive - 1st Line (L1) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 1st Line (L1)

versus trastuzumab
pertuzumab plus trastuzumab vs. trastuzumab 1 noneinconclusive results for: objective responses (ORR)

statistically conclusive 35 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable

suggested 43 % decrease in DOR but the degree if certainty is unassessable

-
versus trastuzumab plus chemotherapy
trastuzumab plus endocrine therapy vs. trastuzumab plus chemotherapy 1 noneinconclusive results for: deaths (OS); progression or deaths (PFS)--
versus trastuzumab plus docetaxel
pertuzumab plus trastuzumab plus docetaxel vs. trastuzumab plus docetaxel 2

statistically conclusive 36 % decrease in progression or deaths (PFS)

statistically conclusive 4.2-fold increase in objective responses (ORR)

-

statistically conclusive 34 % decrease in deaths (OS) but the degree if certainty is unassessable

suggested 31 % decrease in deaths (OS) (extension) but the degree if certainty is unassessable

suggested 31 % decrease in PFS (extension) but the degree if certainty is unassessable

-

la/mBC - HER2 positive - 2nd Line (L2) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 2nd Line (L2)

versus lapatinib
lapatinib plus trastuzumab vs. lapatinib 1 noneinconclusive results for: objective responses (ORR)

suggested 26 % decrease in deaths (OS) but the degree if certainty is unassessable

suggested 26 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable

-
versus lapatinib plus capecitabine
neratinib plus capecitabine vs. lapatinib plus capecitabine 2

statistically conclusive 26 % decrease in progression or deaths (PFS)

suggested 50 % decrease in DOR

inconclusive results for: deaths (OS); objective responses (ORR); Anaemia AE (grade 3-4); Asthenia AE (grade 3-4); Back pain AE (grade 3-4); Constipation AE (grade 3-4); Decreased appetite AE (grade 3-4); Diarrhoea AE (grade 3-4); Fatigue AE (grade 3-4); Headache AE (grade 3-4); Nausea AE (grade 3-4); Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4); Pyrexia AE (grade 3-4); Rash AE (grade 3-4); Stomatitis AE (grade 3-4); Vomiting AE (grade 3-4); Weight decreased AE (grade 3-4)--
versus placebo
neratinib vs. placebo 1 none---
versus trastuzumab plus capecitabine
lapatinib plus capecitabine vs. trastuzumab plus capecitabine 1 noneinconclusive results for: deaths (OS); progression or deaths (PFS); objective responses (ORR)

suggested 4.3-fold increase in DCR but the degree if certainty is unassessable

-
tucatinib plus trastuzumab plus capecitabine vs. trastuzumab plus capecitabine 2 noneinconclusive results for: AE leading to treatment discontinuation (any grade)

statistically conclusive 34 % decrease in deaths (OS) but the degree if certainty is unassessable

statistically conclusive 46 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable

-
versus trastuzumab plus vinorelbine
afatinib plus vinorelbine vs. trastuzumab plus vinorelbine 1 noneinconclusive results for: deaths (OS); progression or deaths (PFS); DOR; objective responses (ORR)--

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons